Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients

Clinical Infectious Diseases

Volumn 32, Issue 5, 2001, Pages 742-751

  Singh, N ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; VIRUS DNA;

ANTIBIOTIC PROPHYLAXIS; CYTOMEGALIC INCLUSION BODY DISEASE; HEALTH CARE COST; HEALTH SURVEY; HUMAN; INFECTION COMPLICATION; INFECTION PREVENTION; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RECIPIENT; REVIEW; TREATMENT PLANNING;

ANTIVIRAL AGENTS; CHEMOPREVENTION; CLINICAL TRIALS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HUMANS; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS;

EID: 0035282381     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/319225     Document Type: Review

References (90)

1. Cytomegalovirus infection following liver transplantation: Review of the literature
2. Cytomegalovirus infections in heart and heart and lung transplant recipients
3. Cytomegalovirus infection and disease after liver transplantation: An overview
4. Ganciclovir, an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients
5. Preemptive ganciclovir therapy in cytomegalovirus seropositive renal transplant recipients
6. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients: A randomized controlled trial
7. Randomized comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver transplant recipients
8. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients
9. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind trial
10. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients: A randomized trial
11. A risk-adapted approach with a short-course of ganciclovir to prevent cytomegalovirus pneumonia in CMV-seropositive recipients of allogeneic bone marrow transplants
12. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia
13. Definitions of cytomegalovirus disease after heart transplantation: Antigenemia as a marker for antiviral therapy
14. Cytomegalovirus PP65 antigenemia monitoring as a guide for preemptive therapy: A cost effective strategy for prevention of cytomegalovirus disease in adult liver transplant recipients
15. Preemptive treatment for the prevention of cytomegalovirus disease
16. Preemptive treatment of cytomegalovirus (CMV) infection can be based solely on frequent shell-vial culture assay in altogeneic hematopoietic cell transplant (ALLO-HCT) patients (PTS)
17. Prevention of CMV disease in allogeneic BMT recipients by cytomegalovirus antigenemia-guided preemptive ganciclovir therapy
18. Cytomegalovirus antigenemia directed pre-emptive prophylaxis with oral versus I.V. ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients: A randomized, controlled trial
19. Preemptive treatment of CMV infection after liver transplantation using oral ganciclovir: Preliminary results
20. Preemptive therapy with oral ganciclovir of cytomegalovirus disease in liver transplant recipients monitored with plasma PCR and leucocyte viral load
21. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection
22. Development of ganciclovir resistance during treatment of primary cytomegalovirus infection after liver transplantation
23. A double-blinded placebo controlled randomized trial evaluating preemptive therapy with oral ganciclovir based on the detection of cytomegalovirus DNA post liver transplantation
24. Protective effect of ganciclovir (G) against cytomegalovirus (CMV) pneumonitis and acute rejection (AR) in lung transplant patients (LTp)
25. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation
26. Efficacy of a 6-week prophylactic ganciclovir regimen and the role of serial cytomegalovirus antibody testing in lung transplant recipients
27. Detection of human cytomegalovirus antigenaemia: A rapid diagnostic technique for predicting cytomegalovirus infection/pneumonitis in lung and heart transplant recipients
28. Comparison of the cost effectiveness of preemptive therapy as directed by CMV antigenemia and prophylaxis with ganciclovir in lung transplant recipients
29. Pharmacokinetic assessment of oral ganciclovir in lung transplant recipients with cystic fibrosis
30. Oral ganciclovir for CMV prevention after lung transplantation
31. Management of herpes virus infections following transplantation
32. Prevention of cytomegalovirus disease in transplant recipients
33. Laboratory monitoring of cytomegalovirus disease: Is polymerase chain reaction the answer?
34. Cytomegalovirus (CMV) antigenemia assay is more sensitive than shell vial cultures for rapid detection of CMV in polymorphonuclear blood leukocytes
35. Antigenemia in the diagnosis and monitoring of active cytomegalovirus infection after liver transplantation
36. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation
37. Comparison of polymerase chain reaction from plasma and buffy coat with antigen detection and occurrence of immunoglobulin M for the demonstration of cytomegalovirus infection after liver transplantation
38. Association of quantitative cytomegalovirus antigenemia with symptomatic infection in solid organ transplant patients
39. The clinical utility of CMV surveillance cultures and antigenemia following bone marrow transplantation
40. A prospective comparison of molecular diagnostic techniques for the early detection of cytomegalovirus in liver transplant recipients
41. Cytomegalovirus DNA in the sera of patients with cytomegalovirus pneumonia
42. Human cytomegalovirus immediate early and late transcripts in peripheral blood leukocytes: Diagnostic value in renal transplant recipients
43. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation
44. Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation
45. Quantity of human cytomegalovirus (CMV) DNAemia as a risk factor for CMV disease in renal allograft recipients: Relationship with donor/recipient CMV serostatus, receipt of augmented methylprednisolone and antithymocyte globulin (ATG)
46. Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma
47. Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients
48. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation
49. Preemptive treatment approach to cytomegalovirus (CMV) infection in solid organ transplant patients: Relationship between compliance with guidelines and prevention of CMV morbidity
50. The cost impact of cytomegalovirus disease in renal transplant recipients
51. The economic impact of cytomegalovirus infection after liver transplantation
52. Cytomegalovirus disease is associated with increased cost and hospital length of stay among orthotopic liver transplant recipients
53. Symptomatic cytomegalovirus infection as a significant risk factor for major infections after cardiac transplantation
54. Increased pulmonary superinfections in cardiac-transplant patients undergoing primary cytomegalovirus infection
55. The independent role of CMV as a risk factor for invasive fungal disease in orthotopic liver transplant recipients
56. Primary cytomegalovirus and opportunistic infections: Incidence in renal transplant recipients
57. High incidence of active cytomegalovirus infection among septic patients
58. Enhanced (cytomegalovirus) viral replication associated with septic bacterial complications in liver transplant recipients
59. Tumor necrosis factor alpha promotes replication and pathogenicity of rat cytomegalovirus
60. Prophylactic ganciclovir treatment reduces fungal as well as cytomegalovirus infections after heart transplantation
61. Cytomegalovirus infection and donor/recipient HLA antigens: Interdependent cofactors in pathogenesis of vanishing bile duct syndrome after liver transplantation
62. The infiuence of HLA matching on cytomegalovirus hepatitis and chronic rejection after liver transplantation
63. Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients
64. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation
65. An association between cytomegalovirus infection and chronic rejection after liver transplantation
66. Association of coronary artery disease with cardiac transplant recipients with cytomegalovirus infection
67. Role of cytomegalovirus infection in the development of coronary artery disease in the transplanted heart
68. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: A post hoc analysis of a randomized, placebo-controlled study
69. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation
70. Cytomegalovirus infection: Enhanced allograft arteriosclerosis is prevented by DHPG prophylaxis in the rat
71. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy
72. Coronary artery disease after hearth transplantation and its relation to cytomegalovirus
73. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: Risk factors and outcome
74. Emergence of ganciclovir-resistant cytomegalovirus disease among solid-organ transplants
75. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection
76. Emergence of clinically significant ganciclovir (GCV)-resistant strains of CMV in solid organ transplant recipients
77. The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation
78. Early emergence of ganciclovir-resistant human cytomegalovirus strains in children with primary combined immunodeficiency
79. Oral ganciclovir usage for cytomegalovirus prophylaxis in organ transplant recipients: Is emergence of resistance imminent?
80. Cost-effectiveness of different strategies of cytomegalovirus prophylaxis in orthotopic liver transplant recipients
81. Cytomegalovirus surveillance and prevention in allogeneic bone marrow transplantation: Examination of a preemptive plan of ganciclovir therapy
82. Prophylaxis of cytomegalovirus infection in liver transplantation: A randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir
83. A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients
84. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis
85. Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients
86. Failure of ganciclovir treatment associated with selection of a ganciclovir resistant cytomegalovirus strain in a lung transplant recipient
87. Ganciclovir resistance as a result of oral ganciclovir in a heart transplant recipient with multiple human cytomegalovirus strains in blood
88. The clinical significance of ganciclovir resistance in a renal transplant patient
89. Prevention of recurrent cytomegalovirus disease in renal and liver transplant recipients: Effect of oral ganciclovir
90. Development of cytomegalovirus resistance to ganciclovir after oral maintenance treatment in a renal transplant recipient